• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

China Medicine Releases White Paper on Developing Recombinant Aflatoxin-Detoxifizyme

Posted on: Wednesday, 9 July 2008, 09:00 CDT

GUANGZHOU, China, July 9 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME; " China Medicine" or " the Company"), a leading distributor and developer of ethical and over-the-counter drugs, traditional Chinese Medicine (TCM), nutritional and dietary supplements, medical devices, and medical formulations in the People's Republic of China (PRC), announced today that it released a white paper on Recombinant Aflatoxin-Detoxifizyme ("rADTZ"). The paper describes the origin, development and history of rADTZ, its scientific basis, and its market potential in the feed, food and health care industries. The white paper is available for download on the Company's website: http://www.chinamedicinecorp.com/adtz.htm .

"We are very excited about the development of rADTZ, which has the potential to detoxify aflatoxin (AFT) in food and feed, and we are currently carrying out experiments on animal feed," said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. "We hope to bring you positive news on the results in the near future."

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company which discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over-the-counter drugs, traditional Chinese medicine products, herbs and dietary supplements. The Company distributes the products to wholesale distributors in 28 provinces and to more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.chinamedicinecorp.com/ .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

Company Contact: Ms. Huizhen Yu Chief Financial Officer China Medicine Corp. Tel: +86-20-8739-1718 Email: konzern08@163.com Web: http://www.chinamedicinecorp.com/ Investor Relations Contact: Mr. Crocker Coulson, President CCG Elite Investor Relations Tel: +1-646-213-1915 Email: crocker.coulson@ccgir.com Mr. Richard Micchelli, Financial Writer CCG Elite Investor Relations Tel: +1-646-454-4516 Email: richard.micchelli@ccgir.com Web: http://www.ccgelite.com/

China Medicine Corporation

CONTACT: Company Contact: Ms. Huizhen Yu, Chief Financial Officer ofChina Medicine Corp., +86-20-8739-1718, or konzern08@163.com, orhttp://www.chinamedicinecorp.com/; or Investor Relations Contact: Mr. CrockerCoulson, President of CCG Elite Investor Relations, +1-646-213-1915, orcrocker.coulson@ccgir.com; or Mr. Richard Micchelli, Financial Writer of CCGElite Investor Relations, +1-646-454-4516, or richard.micchelli@ccgir.com, orhttp://www.ccgelite.com/

Web Site: http://www.chinamedicinecorp.com/

Source: PRNewswire

More News in this Category